Fredrick Van Goor, Ph.D., is the Vice President and Head of Cystic Fibrosis (CF) Research at Vertex Pharmaceuticals, where he provides scientific leadership across the company's research, clinical, regulatory, and commercial teams. He played a key role in the biology efforts that led to the discovery and development of Vertex's four approved CF treatments—Kalydeco, Orkambi, Symdeko, and Trikafta—which address the underlying cause of CF in up to 90% of patients. Dr. Van Goor is also spearheading Vertex's research into nucleic acid therapies aimed at potentially curing CF. Before joining Vertex in 2001, he was a Postdoctoral Fellow at the National Institutes of Health. With over 20 U.S. patents related to CF and technology development, Dr. Van Goor has contributed six book chapters and authored more than 50 research articles in prestigious journals such as the New England Journal of Medicine, Nature Medicine, and the Proceedings of the National Academy of Sciences. He earned his Ph.D. in Biological Sciences from the University of Alberta, Canada.